NCT02083783View on ClinicalTrials.gov

TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)

PHASE3CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

October 31, 2014

Study Completion Date

December 31, 2014

Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
DRUG

TRI102

formulation containing active moiety (amphetamine)

OTHER

Placebo

formulation without active moiety

Trial Locations (5)

27705

Duke University Medical Center, Durham

77007

Bayou City Research, Houston

79423

Westex Clinical Investigation, Lubbock

89128

Center for Psychiatry and Behavioral Medicine, Inc., Las Vegas

92660

Newport Beach Clinical Research Associates, Inc., Newport Beach

All Listed Sponsors
lead

Tris Pharma, Inc.

INDUSTRY

NCT02083783 - TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD) | Biotech Hunter | Biotech Hunter